When was Sydnexis founded?

Sydnexis was founded in 2014 and raised its 1st funding round 3 years after it was founded.

Where is Sydnexis located?

Sydnexis is headquartered in Del Mar, United States.

How many employees does Sydnexis have?

As of Jun 30, 2026, the latest employee count at Sydnexis is 19.

Is Sydnexis a funded company?

Sydnexis is a funded company, having raised a total of $71.5M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 19, 2017.

When was the latest funding round of Sydnexis?

Sydnexis' latest funding was a $***** Series B round on Apr 03, 2025, with participation from 0 investor. Its primary sector is Ophthalmology. In United States, the Ophthalmology sector has seen $1.27B in funding in 2026 to date.

Where does Sydnexis rank among its competitors?

Sydnexis ranks 112th amongst 2653 active competitors, of which 905 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Sydnexis?

Sydnexis' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Sydnexis - 2026 Company Profile, Team, Funding & Competitors

Sydnexis is a series B company based in Del Mar (United States), founded in 2014 by Jacqueline Johnson. It operates as a Developer of a therapeutic formulation for treating myopia. Sydnexis has raised $71.5M in funding from investors like Bluestem Capital, Visionary Ventures and SC Master Fund. The company has 2653 active competitors, including 905 funded and 678 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Sydnexis has developed a proprietary formulation for treating myopia. The patented eye drop formulation SYD-101 is developed to reduce the myopia progression which is associated with numerous serious ophthalmic co-morbidities in children.

Website: sydnexis.com
Email ID: *****@sydnexis.com
Phone Number: +1 **********

Key Metrics

Founded Year

2014

Location

Del Mar, United States

Stage

Series B

Total Funding

$71.5M in 4 rounds

Latest Funding Round

Series B, Apr 03, 2025, $*****

Investors

Bluestem Capital & 5 more

Ranked

112^th among 2653 active competitors

Employee Count

19 as on Jun 30, 2026

Similar Companies

Viridian Therapeutics & 288 more

View Sydnexis' full profile

Sydnexis has raised a total funding of $71.5M over 4 rounds. Its first funding round was on Oct 19, 2017. Sydnexis has 6 institutional investors.

Here is the list of recent funding rounds of Sydnexis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 03, 2025	9682250	Series B	2104402	8006876	7660137	3659551
Apr 24, 2024	1431308	Series B	1839686	8531220	5350593	2533779
Aug 10, 2021	7163568	Series B	4375023	2880118	Visionary Ventures & 2 more	RA Capital Management & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Sydnexis's funding rounds and investors

The founders of Sydnexis is Jacqueline Johnson.

Here are the details of Sydnexis' key team members:

Jacqueline Johnson: Co-Founder & COO of Sydnexis.

View details of Sydnexis's Founder profiles and Board Members

Sydnexis' employee count trend

Sydnexis has 19 employees as of Jun 26. Here is Sydnexis's employee count trend over the years:

Uncover Sydnexis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sydnexis include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Sydnexis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Livzon Pharmaceutical & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
112th	Sydnexis 2014, Del Mar (United States), Series B	Developer of a therapeutic formulation for treating myopia	$71.5M	Longitude Capital, RA Capital Management & 4 others	61/100